

RWE: Win-Win Opportunities for Pharmas and Payers

Joseph Singer, MD

.Vice President Clinical Affairs, HealthCore

The PRISME Forum

Why Real World Evidence?

The Burden of Chronic Disease: A Noticeable Gap in Care in Key Areas

An Intensifying Problem

5% of the population makes up half of US healthcare costs¹

A Growing Issue

By 2030, chronic diseases will affect half of all Americans²

A Costly Situation

75% of total healthcare costs go toward treating chronic disease³




¹ http://facts.kff.org/chart.aspx?ch=1344

² http://www.fightchronicdisease.org/sites/default/files/docs/GrowingCrisisofChronicDiseaseintheUSfactsheet_81009.pdf

³ http://www.kaiseredu.org/Issue-Modules/US-Health-Care-Costs/Background-Brief.aspx

Innovative Payment Models are Increasing in Prevalence

- Emerging US payment models are seeking to align provider and payer interests
- Models with a degree of shared risk continue to evolve, across the care continuum:
 - Pay-for-Performance
 - Hospital-Physician Bundling
 - Episodic Bundling
 - Shared-Savings Models (ACO, PCMH)
- In order to be successful, healthcare entities will need new systems and capabilities



Shifting from Process to Outcomes Measures

Outcomes

Success within the evolving healthcare system requires shifting focus from Activities to Outcomes



Insight


Understanding outcomes requires Insight at the patient level (quality and care) and of total cost



Insight allows an understanding of Gaps and Best Practices in quality, care, and cost



Improve Outcomes with a 360° View of the Patient






Real World Evidence: Potential Application

Through innovative and advanced analytical deliverables developed using claims and electronic health record data, RWE would help support:


- •Patients: Identifying unmet medical needs, improving quality, outcomes, and coordination of patient centered care
- •IDNs / Hospitals: Improving quality of care and outcomes while providing insights into cost containment
- Payers: Analysis of new payment models, risk and outcomes-based contracts
- •Pharma / Biotech: Market analysis to support product innovation for development of reimbursable products and to demonstrate the value of our medicines in improving health outcomes and total cost of care



RWE Support Across the Product Life Cycle



Root of the Evidence Gap



Integration of Key Clinical Data

- •Incorporation of chart-based elements including:
 - Vitals
 - Physical findings
 - Immunizations
 - Social Functioning
 - Family history
 - Prescribed medications (including OTC)
 - Test results
 - Other

Vital Signs

Person ID	Service Department	Observation Date	Observation	Observation Type	Observation Type	Observation Value	Observation Status	Reference Range
PER100001533	Vital Signs	2010-04-18	Diastolic BP	Diastolic BP	NUMERIC	72	Final	60-79
PER100001533	Vital Signs	2010-09-13	Diastolic BP	Diastolic BP	NUMERIC	60	Final	60-79
PER100001533	Vital Signs	2010-04-18	Pulse Description	Pulse Description	TEXT	regular	Final	-
PER100001533	Vital Signs	2009-12-20	Pulse Description	Pulse Description	TEXT	regular	Final	-
PER100001533	Vital Signs	2009-07-29	Pulse rate	Pulse rate	NUMERIC	87	Final	50-80
PER100001533	Vital Signs	2009-12-20	Pulse rate	Pulse rate	NUMERIC	74	Final .	50-80
						no intercostal retractions or		1
PER100001533	Vital Signs	2009-07-29	Respiratory Rate	Respiratory Rate	ONTOLOGY	use of accessory mus	Final	-
								<120
								prehypertension
PER100001533	Vital Signs	2010-04-18	Systolic BP	Systolic BP	NUMERIC	120	Final	130-139
PER100001533	Vital Signs	2010-09-13	Systolic BP	Systolic BP	NUMERIC	105	Final	90-119
PER100001533	Vital Signs	2010-09-13	Weight	Weight	NUMERIC	189	Final	-
PER100001533	Vital Signs	2011-03-17	Weight	Weight	NUMERIC	192	Final	-

Physical Exam Results

Person ID	Service Department	Observation Date	Observation	Observation Type	Observation Type	Observation Value	Observation Status	Reference Range
						no distension. soft and non-		
PER100001533	E&M Physical Exam	2010-09-13	Abdomen Examination	Abdomen Examination	ONTOLOGY	tender without guardin	Final	-
						pulses full and symmetric; no		
PER100001533	E&M Physical Exam	2009-12-20	Carotid Artery Examination	Carotid Artery Examination	ONTOLOGY	bruits	Final	
PER100001533	E&M Physical Exam	2009-12-20	Chest Percussion	Chest Percussion	ONTOLOGY	no duliness	Final	-
PER100001533	E&M Physical Exam	2009-12-20	Cranial Nerves Examination	Cranial Nerves Examination	ONTOLOGY	II - XII grossly intact	Final	-
PER100001533	E&M Physical Exam	2009-12-20	Diabetic Foot Exam	Diabetic Foot Exam	ONTOLOGY	yes	Final	-
PER100001533	E&M Physical Exam	2009-07-29	Eyes Examination	Eyes Examination	ONTOLOGY	conjunctiva and lids normal	Final	
PER100001533	E&M Physical Exam	2009-12-20	Gait Examination	Gait Examination	ONTOLOGY	normal gait; no ataxia	Final	-
						no appearance of anxiety.		
PER100001533	E&M Physical Exam	2009-12-20	Mood-Affect	Mood-Affect	ONTOLOGY	depression, or agitation	Final	
						no cyanosis. clubbing. or		
PER100001533	E&M Physical Exam	2009-12-20	Peripheral Vasculature Examination	Peripheral Vasculature Examination	ONTOLOGY	edema	Final	-
						2 and symmetric with no		
PER100001533	E&M Physical Exam	2009-07-29	Reflex - Deep Tendon Neurologic Exam	Reflex - Deep Tendon Neurologic Exam	ONTOLOGY	pathological reflexes	Final	-
						no nodules. masses.		
PER100001533	E&M Physical Exam	2010-09-13	Thyroid Examination	Thyroid Examination	ONTOLOGY	tenderness. or enlargement	Final	-

Immunizations

Person ID	Service Department	Observation Date	Observation	Observation Type	Observation Type	Observation Value	Observation Status	Reference Range
PER100001533	Immunization	2010-02-04	H1N1 Administered By	H1N1 Administered By	TEXT	MEDICAL PROVIDER	Final	
PER100001533	Immunization	2010-02-04	H1N1 Administration Site	H1N1 Administration Site	ONTOLOGY	Left Deltoid-LD	Final	
PER100001533	Immunization	2010-02-04	H1N1 Expiration Date	H1N1 Expiration Date	TEXT	06/07/2011	Final	-
PER100001533	Immunization	2010-02-04	H1N1 Lot Number	H1N1 Lot Number	TEXT	UP101AA	Final	-
PER100001533	Immunization	2010-02-04	H1N1 Manufacturer	H1N1 Manufacturer	ONTOLOGY	Sanofi Pasteur-PMC	Final	
PER100001533	Immunization	2010-02-04	H1N1 Route of Administration	H1N1 Route of Administration	ONTOLOGY	Intramuscular-IM	Final	
PER100001533	Immunization	2010-02-04	H1N1 Vaccine Information	H1N1 Vaccine Information	TEXT	10/02/09	Final	

Social Functioning

Person ID	Service Department	Observation Date	Observation	Observation Type	Observation Type	Observation Value	Observation Status	Reference Range
PER100001533	E&M Social History	2009-12-20	Social History Reviewed	Social History Reviewed	ONTOLOGY	no changes required	Final	-
PER100001533	E&M Social History	2010-04-18	Social History Reviewed	Social History Reviewed	ONTOLOGY	no changes required	Final	-
PER100001533	E&M Social History	2009-12-20	Social History Status	Social History Status	ONTOLOGY	no changes required	Final	-
PER100001533	E&M Social History	2010-09-13	Social History Status	Social History Status	ONTOLOGY	no changes required	Final	-



Key to Insight Generation

Persisting Longitudinal Patient Record (LPR) at the Database Level

Incorporation of vital signs

A	D	E	F	Н	J	L	M	N	0	Р	Q
4 Result Indexes	<u> </u>										
5	service_department	observation_date	observation_time	observation_type	observation_value	reference_range	normality	unit			
302 PER10000153	3 Vital Signs	3/18/2011	0:00:08	Diastolic BP	70	60-79		mmHg			
303 PER10000153	3 Vital Signs	3/17/2011	20:00:00	Diastolic BP	70	60-79					
304 PER10000153	3 Vital Signs	9/13/2010	20:00:00	Diastolic BP	60	60-79					
305 PER10000153	3 Vital Signs	4/18/2010	20:00:00	Diastolic BP	72	60-79					
306 PER10000153	3 Vital Signs	12/20/2009	19:00:00	Diastolic BP	76	60-79					
307 PER10000153	3 Vital Signs	7/29/2009	20:00:00	Diastolic BP	70	60-79					
308 PER10000153	3 Vital Signs	3/18/2011	0:00:08	Measured Weight	192	-		lb			
309 PER10000153	3 Vital Signs	3/18/2011	0:00:08	Pulse rate	64	50 - 80		/min			
310 PER10000153	3 Vital Signs	3/17/2011	20:00:00	Pulse rate	64	50 - 80					
311 PER10000153	3 Vital Signs	9/13/2010	20:00:00	Pulse rate	68	50 - 80					
312 PER10000153	3 Vital Signs	4/18/2010	20:00:00	Pulse rate	78	50 - 80					
313 PER10000153	3 Vital Signs	12/20/2009	19:00:00	Pulse rate		50 - 80					
314 PER10000153	3 Vital Signs	7/29/2009	20:00:00	Pulse rate	87	50 - 80					
315 PER10000153	3 Vital Signs	3/18/2011		Systolic BP	105	90-119		mmHg			
316 PER10000153	_	3/17/2011	20:00:00	Systolic BP		90-119					
317 PER10000153	3 Vital Signs	9/13/2010	20:00:00	Systolic BP	105	90-119					
318 PER10000153	3 Vital Signs	4/18/2010	20:00:00	Systolic BP	120	<120 prehypertension 130-139					
319 PER10000153	_	12/20/2009	19:00:00	Systolic BP	110	90-119					
320 PER10000153		7/29/2009		Systolic BP	120	<120 prehypertension 130-139					
321 PER10000153		3/17/2011	20:00:00		192						
322 PER10000153	-	9/13/2010			189	-					
323 PER10000153		4/18/2010			190						
324 PER10000153	-	12/20/2009			190	-					
325 PER10000153	_	7/29/2009		-	183	-					
326 PER10000153	3 Vital Signs	3/17/2011	20:00:00	Weight (kg)	87.27						
327 PER10000153	3 Vital Signs	9/13/2010	20:00:00	Weight (kg)	85.91	-					
328 PER10000153	3 Vital Signs	4/18/2010	20:00:00	Weight (kg)	86.36	-					
329 PER10000153		12/20/2009	19:00:00	Weight (kg)	86.36						
330 PER10000153	3 Vital Signs	7/29/2009	20:00:00	Weight (kg)	83.18	-					
173											

Key to Insight Generation

Persisting Longitudinal Patient Record (LPR) at the Database Level

A	D	E	F	Н	J.	ι	M	N	0	P	Q
Result Indexes	lpo	ju .		X							
	service_department	observation_date		20 27 4 3 4 4 3 4 5 4 4 4 4 5 4 5 4 5 4 5 4 5	observation_value	reference_range	normality	unit			
Developed in the section of Products	Blood Count Test	4/18/2010		Hemoglobin A1c	5.8						
1	Blood Count Test	3/17/2011		Hemoglobin A1c	7.2	-					
The state of the s	Evaluation and Management	9/13/2010		Orientation	oriented to time, place, and person	-					a.
	Evaluation and Management	12/20/2009		Gait Examination	normal gait; no ataxia						
	Evaluation and Management	9/13/2010		Coronary Heart Disease (CHD). Calculated 10 yr Mortality Risk	18	-					
	Evaluation and Management	9/13/2010		Past Medical History	reviewed - no changes required						
	Evaluation and Management	9/13/2010		Mood-Affect	no appearance of anxiety, depression, or agitation						
	Evaluation and Management	4/18/2010		Mood-Affect	no appearance of anxiety, depression, or agitation	-					
	Evaluation and Management	3/17/2011		Social History Reviewed	reviewed - no changes required	-					
	Evaluation and Management	12/20/2009		History of Peripheral Vascular Disease	no	-					
	Evaluation and Management	12/20/2009		History of Hypertension	no	-					
	Evaluation and Management	12/20/2009		History of Diabetes Mellitus	yes	-					
	Evaluation and Management	12/20/2009		History of CVA or TIA	no	-					
	Evaluation and Management	12/20/2009		History of Coronary Artery Disease	no	-					
	Evaluation and Management	9/13/2010		Chief Complaint	Lipid Management	-					
	Evaluation and Management	12/20/2009		History of HDL (high densisty lipoproteins) <35	yes	-					
PER100001533		3/17/2011		Total Protein	7.1						
PER100001533		9/13/2010		T Chol/HDL Ratio	3.95						
PER100001533		9/13/2010		Glucose-Serum	119	-					
PER100001533	Medical Care	2/4/2010		H1N1 Expiration Date	6/7/2011	-					
PER100001533		7/29/2009		Respiratory Rate	no intercostal retractions or use of accessory mus	-					
	Patient Exam/Assessment	12/20/2009		Diabetic Foot Exam	yes	-					
PER100001533	,	2/1/2012		Brand Description	ONETOUCH ULTRA TEST_STRP	-					
PER100001533	,	2/1/2012		Brand Description	VITAMIN D 1000 UNIT CAPS	-					
PER100001533	'	2/4/2010		H1N1 Lot Number	UP101AA	-					
PER100001533		2/4/2010		H1N1 Route of Administration	Intramuscular-IM	-					
PER100001533	,	2/4/2010		H1N1 Manufacturer	Sanofi Pasteur-PMC	-					
PER100001533	Pharmacy	4/18/2010	20:00:00	No Known Medications	F	-					
	Preventive Medicine	2/4/2010		H1N1 Administered By	Pearce, LPN, Sandra	-					
	Preventive Medicine	2/4/2010		H1N1 Vaccine Information	10/2/2009	-					
PER100001533	Preventive Medicine	9/13/2010	20:00:00	HIB 4 Months	51						
PER100001533	Preventive Medicine	4/18/2010		HIB 4 Months	79	-					
PER100001533	Preventive Medicine	7/23/2009		HIB 4 Months	17	-					
PER100001533	Preventive Medicine	2/4/2010	19:00:00	H1N1 Administration Site	Left Deltoid-LD	-					
PER100001533	Tumor Marker	1/15/2010		Prostate-specific Ag. Serum		<=4.0	Abnormal-High	ng/mL			
PER100001533	Tumor Marker	1/15/2010	19:00:00	% Free PSA	22	>25	Abnormal-Low	%			
					16 br/>THE ESTIMATED PROBABILITY OF CANCER						
					VARIES WITH AGE. VARIES WITH AGE. AGE. ADD						
					DIGITAL RECTAL EXAMINATION br/>(DRE)						
					RESULTS. REFERENCE: CATALONA. ET AL.: JAMA						
PER100001533	Tumor Marker	1/15/2010	19:00:00	Risk of Prostate Cancer	279: 1532-1547 (1998)	-		%			
PER100001533	Tumor Marker	1/15/2010	19:00:00	PSA. Free	1.3	-		ng/mL			
01 PER100001533	Tumor Marker	1/15/2010	19:00:00	PSA. Free	1.3	-		ng/mL			

Clinical Enrichment

Valid Quality of Care Measurement

Numerator Name*

HEDIS LDL Cholesterol Screening - Compliant

HEDIS Glaucoma Screening - Compliant

HEDIS HbA1c Control - Good


HEDIS Blood Pressure < 140/90 & Within Year - Compliant


HEDIS Nephropathy Screening - Compliant


HEDIS Retinopathy Screening - Compliant


Diabetes Total:


	Claims & Lab		Claims, Lab & EMR Data			% Yield			
Numerator	Denominator	Percentage	Numerator	Denominator	Percentage	Numerator	umerator Denominator		
30	79	38%	26	101	26%	-13%	28%	-32%	
12	31	39%	28	75	37%	133%	142%	-4%	
5	46	11%	20	82	24%	300%	78%	124%	
1	63	2%	96	141	68%	9500%	124%	4189%	
12	48	25%	15	80	19%	25%	67%	-25%	
12	37	32%	25	50	50%	108%	35%	54%	
72	304	24%	210	529	40%	192%	74%	68%	















^{*}Note: ~1500 member population. Select enrichment measures only

Electronic Healthcare Data Proliferation

Value is Unlocked with Integration




Each Data Source Contributes Unique Information

Health Plan Claims provides a broad view, insight into cost of care & information such as actual fill (Rx) history

Outpatient Chart Information provides rich clinical information and such endpoints as prescribed medications, lab and test results, OTC advice and reported use, family history

Inpatient Chart Information provides rich clinical information on procedures, conditions treated, medication use, lab and test results

A Necessary Connection



Key Learnings to Date





Stakeholder alignment is key



Many are not yet ready from a technological perspective



Trust between parties has to be established



Understanding of data complexity and ability to integrate data is essential



Development and implementation costs can be high



The results can be transformational for health and healthcare

Risks of Big Data in RWE

- Addressing issues of semantic interoperability and disparate ontologies and nomenclatures
- Statistical significance needs to correlate with clinical and economic significance
- HIPAA compliance becomes more complicated; especially in rare diseases
- State specific regulatory framework
- Awareness of data limitations and inapparent confounders
- Most reporting software has not been designed to integrate detailed clinical information



RWE Support Across the Product Life Cycle

